What is Biophytis?
Biophytis operates at the intersection of advanced medical research and pharmaceutical development, focusing on age-related and degenerative conditions. The company's core value proposition centers on its lead candidate, BIO101, which is currently undergoing rigorous evaluation for indications such as sarcopenia, Duchenne muscular dystrophy, and obesity. By targeting muscle loss and metabolic decline, Biophytis addresses critical unmet needs in the aging population, establishing itself as a pivotal player in the longevity and regenerative medicine market.
The company's market position is bolstered by its ability to attract high-caliber institutional interest, which provides the necessary runway to sustain long-term clinical development. As it continues to refine its therapeutic platform, Biophytis remains focused on translating scientific innovation into scalable, patient-centric solutions.
How much funding has Biophytis raised?
Biophytis has raised a total of $67.2M across 5 funding rounds:
Share Placement
$6.9M
Share Placement
$11.7M
Debt
$38.1M
Private Equity
$8.9M
Stock/Share Issuance
$1.6M
Share Placement (2020): $6.9M, investors not publicly disclosed
Share Placement (2020): $11.7M, investors not publicly disclosed
Debt (2021): $38.1M supported by Atlas Capital Group
Private Equity (2025): $8.9M featuring BlackRock and Atlas Capital
Stock/Share Issuance (2026): $1.6M, investors not publicly disclosed
Key Investors in Biophytis
BlackRock
A global investment management firm providing comprehensive financial services, including risk management and alternative investments for institutional and individual clients.
Atlas Capital Group
A specialized real estate investment and development firm with a focus on providing comprehensive services to stakeholders across major markets in New York and Los Angeles.
Atlas Capital
A proven real estate investor and manager with over 45 years of experience, focusing on value-add projects that generate stable, long-term cash flows.
What's next for Biophytis?
With the recent capital injection, Biophytis is poised to scale its clinical operations and potentially expedite the commercialization pathway for its lead assets. The strategic focus will likely shift toward finalizing global trial data and strengthening its intellectual property portfolio. Investors are closely monitoring the progress of BIO101, as successful outcomes could significantly alter the standard of care for muscle-wasting disorders.
Looking ahead, the company must leverage this financial backing to maintain its competitive edge in the biotechnology landscape. Continued investment in research and development, combined with strategic partnerships, will be essential for Biophytis to achieve its long-term objective of delivering transformative therapies to market, thereby solidifying its reputation as a leader in the treatment of degenerative diseases.
